Allopregnanolone levels and symptom improvement in severe premenstrual syndrome

Journal of Clinical Psychopharmacology

Volumn 22, Issue 5, 2002, Pages 516-520

  Freeman, Ellen W ^a   Frye, Cheryl A ^a   Rickels, Karl ^a   Martin, Paula A G ^a   Smith, Sheryl S ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ANTIDEPRESSANT AGENT; DESIPRAMINE; PLACEBO; SERTRALINE;

ADULT; APPETITE; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MOOD; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SERUM; STRESS; SYMPTOM; TREATMENT OUTCOME;

EID: 0036785068     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200210000-00013     Document Type: Article

References (27)

1. Paul SM, Purdy RH. Neuroactive steroids. FASEB J 1992;6:2311-22.
2. A receptor expression and function during progesterone treatment and withdrawal. Mol Pharmacol 2000;57:1262-70.
3. A receptor regulation: heterologous uncoupling of modulatory site interactions induced by chronic steroid, barbiturate, benzodiazepines or GABA treatment in culture. Brain Res 1996;707:100-9.
4. Purdy RH, Morrow AL, Moore PH, et al. Stress-induced elevations of γ-aminobutyric acid type A receptor-active steroids in the rat brain. Proc Natl Acad Sci U S A 1991;88:4553-7.
5. Genazzani AR, Petraglia F, Bernardi F, et al. Circulating levels of allopregnanolone in humans: gender, age and endocrine influences. Clin Endocrinol Metab 1998;83:2099-103.
6. Monteleone P, Luisi S, Tonetti A, et al. Allopregnanolone concentrations and premenstrual syndrome. Eur J Endocrinol 2000;142: 269-73.
7. Rapkin AJ, Morgan M, Goldman L, et al. Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 1997;90:709-14.
8. Ströhle A, Romeo E, Hermann B, et al. Concentrations of 3α-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry 1999;45:274-7.
9. Girdler SS, Straneva PA, Light KC, et al. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry 2001;49:788-97.
10. Bicikova M, Dibbelt L, Hill M, et al. Allopregnanolone in women with premenstrual syndrome. Horm Metab Res 1998;30:227-30.
11. Wang M, Seippel L, Purdy RH, et al. Relationship between symptom severity and steroid variation in women with premenstrual syndrome. J Clin Endocrinol Metab 1996;81:1076-82.
12. Schmidt PJ, Purdy RH, Moore PH, et al. Circulating levels of anxiolytic steroids in the luteal phase in women with premenstrual syndrome and in control subjects. J Clin Endocrinol Metab 1994; 79:1256-60.
13. Freeman EW, Purdy RH, Coutifaris C, et al. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology 1993;58:4780-4.
14. Freeman EW, Rickels K, Sondheimer SJ, et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch Gen Psychiatry 1999;56:932-9.
15. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res 1996;75: 97-106.
16. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Version 2.0 (SCID-1/P). New York: Biometrics Research Dept., New York State Psychiatric Institute, 1995.
17. Purdy RH, Moore PH, Narasimha Roa P, et al. Radioimmunoassay of 3α-hydroxy-5α-pregnan-20-one in rat and human plasma. Steroids 1990;55:290-6.
18. Frye CA, Petralia SM, Rhodes ME. Estrous cycle and sex differences in performance on anxiety tasks coincide with increases in hippocampal progesterone and 3a,5a-THP. Pharmacol Biochem Behav 2000; 76:587-96.
19. Rodbard D, Hutt DM. Statistical analysis of radioimmunoassay and immunoradiometric assays: a generalized, weighted iterative, least squares method for logistic curve fitting. In: International Atomic Energy Agency, ed. Symposium on radioimmunoassay and related procedures in medicine. New York: Uniput, 1974.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg 1960;23:56-62.
21. Sundstrom I, Andersson A, Nyberg S, et al. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinol 1998;67:126-38.
22. LeMellado JM, VanDriel M, Coupland NJ, et al. Response to flumazenil in women with premenstrual dysphoric disorder. Am J Psychiatry 2000;157:821-3.
23. Schmidt PJ, Grover GN, Rubinow DR. Alprazolam in the treatment of premenstrual syndrome. Arch Gen Psychiatry 1993;50:467-73.
24. Freeman EW, Rickels K, Sondheimer SJ, et al. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995;274:51-7.
25. A receptor subunit levels in association with increased anxiety in the female rat. Brain Res 2001;910:55-66.
26. A receptor α4 subunit in association with increased anxiety. J Neurosci 1998;18:5275-84.
27. Griffin LD, Mellon SH. Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci U S A 1999;96:13512-7.